Switch to:

Fate Therapeutics Enterprise Value

: $3,732.64 Mil (As of Today)
View and export this data going back to 2013. Start your Free Trial

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Fate Therapeutics's Enterprise Value is $3,732.64 Mil. Fate Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2020 was $-116.54 Mil. Therefore, Fate Therapeutics's EV-to-EBIT ratio for today is -32.03.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Fate Therapeutics's Enterprise Value is $3,732.64 Mil. Fate Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2020 was $-113.87 Mil. Therefore, Fate Therapeutics's EV-to-EBITDA ratio for today is -32.78.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Fate Therapeutics's Enterprise Value is $3,732.64 Mil. Fate Therapeutics's Revenue for the trailing twelve months (TTM) ended in Jun. 2020 was $13.21 Mil. Therefore, Fate Therapeutics's EV-to-Revenue ratio for today is 282.54.


Fate Therapeutics Enterprise Value Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Fate Therapeutics Annual Data
Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Enterprise Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.20 22.46 235.54 643.90 1,287.54

Fate Therapeutics Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Enterprise Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,206.37 909.62 1,287.54 1,560.32 2,525.82

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Fate Therapeutics Enterprise Value Distribution

* The bar in red indicates where Fate Therapeutics's Enterprise Value falls into.



Fate Therapeutics Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Fate Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2019 is calculated as

Fate Therapeutics's Enterprise Value for the quarter that ended in Jun. 2020 is calculated as

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Fate Therapeutics  (NAS:FATE) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Fate Therapeutics's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=3732.642/-116.537
=-32.03

Fate Therapeutics's current Enterprise Value is $3,732.64 Mil.
Fate Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2020 was -26.209 (Sep. 2019 ) + -27.764 (Dec. 2019 ) + -34.492 (Mar. 2020 ) + -28.072 (Jun. 2020 ) = $-116.54 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Fate Therapeutics's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=3732.642/-113.874
=-32.78

Fate Therapeutics's current Enterprise Value is $3,732.64 Mil.
Fate Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2020 was -25.622 (Sep. 2019 ) + -27.141 (Dec. 2019 ) + -33.787 (Mar. 2020 ) + -27.324 (Jun. 2020 ) = $-113.87 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Fate Therapeutics's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=3732.642/13.211
=282.54

Fate Therapeutics's current Enterprise Value is $3,732.64 Mil.
Fate Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2020 was 2.429 (Sep. 2019 ) + 2.802 (Dec. 2019 ) + 2.515 (Mar. 2020 ) + 5.465 (Jun. 2020 ) = $13.21 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Fate Therapeutics Enterprise Value Related Terms


Fate Therapeutics Enterprise Value Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)